Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
Authors:
Open Access
- 9 January 2007
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 96 (2) , 269-276
Abstract
Antitumour activity of docetaxel (Taxotere®) in hormone-dependent (HD) and hormone-independent (HID) prostate cancer PAC120 xenograft model was previously reported, and its level was associated with HER2 protein expression. In the present study, we evaluate the antitumour effects of docetaxel combined with trastuzumab (Herceptin®), an anti-HER2 antibody. Although trastuzumab alone had no effect on tumour growth, it potentiated the antitumour activity of docetaxel in HD tumours and more strongly in HID variants. Using the HID28 variant, we show that docetaxel treatment of tumour-bearing mice induces an increased HER2 mRNA expression of the tyrosine kinase receptor of 25-fold 24 h after docetaxel treatment, while HER2 protein and p-AKT decreased. This was followed by an increase of HER2 protein 3 days (two-fold) after docetaxel treatment and by a strong HER2 release in the serum of treated mice; expression of phospho-ERK, p27, BCL2 and HSP70 concomitantly increased. Similar molecular alterations were induced by docetaxel plus trastuzumab combination, except for that there was a transient and complete disappearance of AR and HSP90 proteins 24 h after treatment. We show that in addition to its known effects on tubulin and mitotic spindles, docetaxel induces complex signalisation pathway mechanisms in surviving cells, including HER2, which can be pharmacologically targeted. This study suggests that the docetaxel/trastuzumab combination may prove an effective therapeutic approach for HER2-expressing hormone-refractory prostate cancer.Keywords
This publication has 32 references indexed in Scilit:
- Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 2005
- Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinomaCancer, 2004
- ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cellsInternational Journal of Cancer, 2003
- Androgen receptor gene amplification and protein expression in hormone refractory prostate cancerBritish Journal of Cancer, 2003
- A requirement for MAP kinase in the assembly and maintenance of the mitotic spindleJournal of Cell Biology, 2003
- HER‐2/neu is overexpressed infrequently in patients with prostate carcinomaCancer, 2002
- Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate CancerThe American Journal of Pathology, 2002
- Clinical and Experimental Progression of a New Model of Human Prostate Cancer and Therapeutic ApproachThe American Journal of Pathology, 2001
- HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate CancerAmerican Journal of Clinical Pathology, 2001
- Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancerSeminars in Oncology, 2001